{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:52:55Z","timestamp":1764251575201},"reference-count":60,"publisher":"Bentham Science Publishers Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>68Ga-PSMA is a widely useful PET\/CT tracer for prostate cancer imaging. Being a transmembrane protein acting as a glutamate carboxypeptidase enzyme, PSMA is highly expressed in prostate cancer cells. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. Several studies documented bio-distribution and pitfalls of 68Ga-PSMA as well as of 64Cu- PSMA. No data are reported on differences between these two variants of PSMA. Our aim was to evaluate physiological distribution of these two tracers and to analyze false positive cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We examined tracer bio-distribution in prostate cancer patients with negative 68Ga-PSMA PET\/CT (n=20) and negative 64Ga-PSMA PET\/CT (n=10). A diagnostic pitfall for each tracer was documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Bio-distribution of both tracers was similar, with some differences due to renal excretion of 68Ga- PSMA and biliary excretion of 64Cu-PSMA. 68Ga-PSMA uptake was observed in sarcoidosis while 64Cu- PSMA uptake was recorded in pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion:<\/jats:title><jats:p>Both tracers may present similar bio-distribution in the human body, with similar uptake in exocrine glands and high intestinal uptake. Similarly to other tracers, false positive cases cannot be excluded in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The knowledge of difference in bio-distribution between two tracers may help in interpretation of PET data. Diagnostic pitfalls can be documented, due to the possibility of PSMA uptake in inflammation. Our results are preliminary to future studies comparing diagnostic accuracies of 68Ga-PSMA and 64Cu-PSMA.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874471012666190515090755","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T03:47:52Z","timestamp":1558410472000},"page":"238-246","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["68Ga\/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers"],"prefix":"10.2174","volume":"12","author":[{"given":"Ferdinando","family":"Calabria","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Theranostics, National Public Hospital \"Mariano Santo\", 87100, Cosenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pichler","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, Kepler University Hospital, Neuromed Campus, Wagner-Jauregg Weg 15, A-4021 Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Leporace","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Theranostics, National Public Hospital \"Mariano Santo\", 87100, Cosenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Wolfsgruber","sequence":"additional","affiliation":[{"name":"Department of Urology, Steyr Hospital, Steyr, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Coscarelli","sequence":"additional","affiliation":[{"name":"Casa Protetta San Pio e Madonna Immacolata, Corigliano Calabro (CS), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Dunzinger","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, Kepler University Hospital, Neuromed Campus, Wagner-Jauregg Weg 15, A-4021 Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University \"Tor Vergata\", 00133, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Lucio","family":"Cascini","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Nuclear Medicine Unit, Magna Graecia University, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bagnato","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Theranostics, National Public Hospital \"Mariano Santo\", 87100, Cosenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1021\/jm100623e","volume":"22","author":"Banerjee S.R.","year":"2010","unstructured":"Banerjee S.R.; Pullambhatla M.; Byun Y.; Nimmagadda S.; Green G.; Fox J.J.; Horti A.; Mease R.C.; Pomper M.G.; 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010,22,5333-5341","journal-title":"J Med Chem"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"Afshar-Oromieh A.","year":"2013","unstructured":"Afshar-Oromieh A.; Malcher A.; Eder M.; Eisenhut M.; Linhart H.G.; Hadaschik B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013,40,486-495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12149-017-1207-y","volume":"31","author":"Sanli Y.","year":"2017","unstructured":"Sanli Y.; Kuyumcu S.; Sanli O.; Buyukkaya F.; \u0130riba\u015f A.; Alcin G.; Darendeliler E.; Ozluk Y.; Yildiz S.O.; Turkmen C.; Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET\/CT in patients with recurrent prostate cancer. Ann Nucl Med 2017,31,709-717","journal-title":"Ann Nucl Med"},{"key":"ref=4","first-page":"225","volume":"18","author":"Verburg F.A.","year":"2017","unstructured":"Verburg F.A.; Pfister D.; Drude N.I.; Mottaghy F.M.; Behrendt F.F.; PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent\/metastatic prostate cancer. Nuklearmedizin 2017,18,225-232","journal-title":"Nuklearmedizin"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","volume":"41","author":"Bluemel C.","year":"2016","unstructured":"Bluemel C.; Krebs M.; Polat B.; Linke F.; Eiber M.; Samnick S.; Lapa C.; Lassmann M.; Riedmiller H.; Czernin J.; Rubello D.; Bley T.; Kropf S.; Wester H.J.; Buck A.K.; Herrmann K.; 68Ga-PSMA-PET\/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET\/CT. Clin Nucl Med 2016,41,515-521","journal-title":"Clin Nucl Med"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"Afshar-Oromieh A.","year":"2012","unstructured":"Afshar-Oromieh A.; Haberkorn U.; Eder M.; Eisenhut M.; Zechmann C.M.; [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012,39,1085-1086","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","volume":"42","author":"Kratochwil C.","year":"2015","unstructured":"Kratochwil C.; Giesel F.L.; Eder M.; Afshar-Oromieh A.; Benesova M.; Mier W.; Kopka K.; Haberkorn U.; [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015,42,987-988","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cpet.2016.12.001","volume":"12","author":"Singh A.","year":"2017","unstructured":"Singh A.; Kulkarni H.R.; Baum R.P.; Imaging of prostate cancer using 64Cu-Labeled Prostate-specific membrane antigen ligand. PET Clin 2017,12,193-203","journal-title":"PET Clin"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.urology.2017.04.019","volume":"106","author":"Cantiello F.","year":"2017","unstructured":"Cantiello F.; Gangemi V.; Cascini G.L.; Calabria F.; Moschini M.; Ferro M.; Musi G.; Buttic\u00e8 S.; Salonia A.; Briganti A.; Damiano R.; Diagnostic Accuracy of 64Copper prostate-specific membrane antigen positron emission tomography\/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience. Urology 2017,106,139-145","journal-title":"Urology"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","volume":"7","author":"Umbricht C.A.","year":"2017","unstructured":"Umbricht C.A.; Bene\u0161ov\u00e1 M.; Schmid R.M.; T\u00fcrler A.; Schibli R.; van der Meulen N.P.; M\u00fcller C.; 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res 2017,7,9","journal-title":"EJNMMI Res"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/RLU.0000000000001881","volume":"43","author":"Strele-Trieb P.","year":"2017","unstructured":"Strele-Trieb P.; Dunzinger A.; Sonnberger M.; Wolfsgruber J.; Pichler R.; Uptake of 68Ga-Prostate-specific membrane antigen pet in adrenal gland: a potential pitfall. Clin Nucl Med 2017,43,50-51","journal-title":"Clin Nucl Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/RLU.0000000000001871","volume":"43","author":"Jochumsen M.R.","year":"2018","unstructured":"Jochumsen M.R.; Dias A.H.; Bouchelouche K.; Benign traumatic rib fracture: a potential pitfall on 68Ga-prostate-specific membrane Antigen PET\/CT for Prostate Cancer. Clin Nucl Med 2018,43,38-40","journal-title":"Clin Nucl Med"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000001222","volume":"41","author":"Gykiere P.","year":"2016","unstructured":"Gykiere P.; Goethals L.; Everaert H.; Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET\/CT. Clin Nucl Med 2016,41,e346-e347","journal-title":"Clin Nucl Med"},{"key":"ref=14","first-page":"65","volume":"36","author":"Elri T.","year":"2017","unstructured":"Elri T.; Aras M.; Salihoglu Y.S.; Erdemir R.U.; Cabuk M.; A potential pitfall in the use of 68Ga-PSMA PET\/CT: anthracosis. Rev Esp Med Nucl Imagen Mol 2017,36,65-66","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/RLU.0000000000001084","volume":"41","author":"Kanthan G.L.","year":"2016","unstructured":"Kanthan G.L.; Drummond J.; Schembri G.P.; Izard M.A.; Hsiao E.; Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET\/CT. Clin Nucl Med 2016,41,331-332","journal-title":"Clin Nucl Med"},{"key":"ref=16","first-page":"335","volume":"36","author":"Calabria F.","year":"2017","unstructured":"Calabria F.; Gangemi V.; Gull\u00e0 D.; Schillaci O.; Cascini G.L.; 64Cu-PSMA uptake in meningioma: a potential pitfall of a promising radiotracer. Rev Esp Med Nucl Imagen Mol 2017,36,335-336","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"ref=17","first-page":"81","volume":"3","author":"Silver D.A.","year":"1997","unstructured":"Silver D.A.; Pellicer I.; Fair W.R.; Heston W.D.; Cordon-cardo C.; Prostate specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997,3,81-85","journal-title":"Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1148\/radiographics.19.1.g99ja0761","volume":"19","author":"Shreve P.D.","year":"1999","unstructured":"Shreve P.D.; Anzai Y.; Wahl R.L.; Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999,19,61-77","journal-title":"Radiographics"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1148\/rg.245035725","volume":"24","author":"Kostakoglu L.","year":"2004","unstructured":"Kostakoglu L.; Hardoff R.; Mirtcheva R.; Goldsmith S.J.; PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004,24,1411-1431","journal-title":"Radiographics"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.semnuclmed.2015.02.006","volume":"45","author":"Corrigan A.J.","year":"2015","unstructured":"Corrigan A.J.; Schleyer P.J.; Cook G.J.; Pitfalls and artifacts in the use of PET\/CT in oncology imaging. Semin Nucl Med 2015,45,481-499","journal-title":"Semin Nucl Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ans.12834","volume":"86","author":"Flukes S.","year":"2016","unstructured":"Flukes S.; Lenzo N.; Moschilla G.; Sader C.; Positron emission tomography-positive thyroid nodules: rate of malignancy and histological features. ANZ J Surg 2016,86,487-491","journal-title":"ANZ J Surg"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s002590050597","volume":"26","author":"Cook G.J.","year":"1999","unstructured":"Cook G.J.; Maisey M.N.; Fogelman I.; Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999,26,1363-1378","journal-title":"Eur J Nucl Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/RLU.0000000000001318","volume":"41","author":"Calabria F.F.","year":"2016","unstructured":"Calabria F.F.; Chiaravalloti A.; Jaffrain-Rea M.L.; Zinzi M.; Sannino P.; Minniti G.; Rubello D.; Schillaci O.; 18F-DOPA PET\/CT physiological distribution and pitfalls: experience in 215 patients. Clin Nucl Med 2016,41,753-760","journal-title":"Clin Nucl Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nucmedbio.2017.04.004","volume":"51","author":"Calabria F.","year":"2017","unstructured":"Calabria F.; Chiaravalloti A.; Cicci\u00f2 C.; Gangemi V.; Gull\u00e0 D.; Rocca F.; Gallo G.; Cascini G.L.; Scillacio O.; PET\/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET\/CT bio-distribution and pitfalls. A southern Italian experience. Nucl Med Biol 2017,51,40-54","journal-title":"Nucl Med Biol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.2174\/1381612821666150818110422","volume":"21","author":"Calabria F.","year":"2015","unstructured":"Calabria F.; Gallo G.; Schillaci O.; Cascini G.L.; Bio-distribution, imaging protocols and diagnostic accuracy of pet with tracers of lipogenesis in imaging prostate cancer: a comparison between 11C-choline, 18Ffluoroethylcholine and 18F-methylcholine. Curr Pharm Des 2015,21,4738-4747","journal-title":"Curr Pharm Des"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cpet.2014.03.001","volume":"9","author":"Beheshti M.","year":"2014","unstructured":"Beheshti M.; Haroon A.; Bomanji J.B.; Langsteger W.; Fluorocholine PET\/computed tomography: physiologic uptake, benign findings, and pitfalls. PET Clin 2014,9,299-306","journal-title":"PET Clin"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1148\/rg.2016150135","volume":"36","author":"Welle C.L.","year":"2016","unstructured":"Welle C.L.; Cullen E.L.; Peller P.J.; Lowe V.J.; Murphy R.C.; Johnson G.B.; Binkovitz L.A.; C-choline PET\/CT in recurrent prostate cancer and nonprostatic neoplastic processes. Radiographics 2016,36,279-292","journal-title":"Radiographics"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1097\/RLU.0000000000001672","volume":"42","author":"Kirchner J.","year":"2017","unstructured":"Kirchner J.; Schaarschmidt B.M.; Sawicki L.M.; Heusch P.; Hautzel H.; Ermert J.; Rabenalt R.; Antoch G.; Buchbender C.; Evaluation of practical interpretation hurdles in 68Ga-PSMA PET\/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin Nucl Med 2017,42,e322-e327","journal-title":"Clin Nucl Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/RLU.0000000000001466","volume":"42","author":"Vellani C.","year":"2017","unstructured":"Vellani C.; Hodoli\u010d M.; Chytiris S.; Trifir\u00f2 G.; Rubello D.; Colletti P.M.; Early and delayed 18F-FCH PET\/CT imaging in parathyroid adenomas. Clin Nucl Med 2017,42,143-144","journal-title":"Clin Nucl Med"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/neuonc\/nou131","volume":"17","author":"Afshar-Oromieh A.","year":"2015","unstructured":"Afshar-Oromieh A.; Wolf M.B.; Kratochwil C.; Giesel F.L.; Combs S.E.; Dimitrakopoulou-Strauss A.; Gnirs R.; Roethke M.C.; Schlemmer H.P.; Haberkorn U.; Comparison of Ga-DOTATOC-PET\/CT and PET\/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro-oncol 2015,17,312-319","journal-title":"Neuro-oncol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"Gerster-Gilli\u00e9ron K.","year":"2015","unstructured":"Gerster-Gilli\u00e9ron K.; Forrer F.; Maecke H.; Mueller-Brand J.; Merlo A.; Cordier D.; 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med 2015,56,1748-1751","journal-title":"J Nucl Med"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s00259-016-3424-3","volume":"43","author":"Pfob C.H.","year":"2016","unstructured":"Pfob C.H.; Ziegler S.; Graner F.P.; K\u00f6hner M.; Schachoff S.; Blechert B.; Wester H.J.; Scheidhauer K.; Schwaiger M.; Maurer T.; Eiber M.; Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2016,43,1962-1970","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/cbr.2015.1964","volume":"31","author":"Grubm\u00fcller B.","year":"2016","unstructured":"Grubm\u00fcller B.; Baum R.P.; Capasso E.; Singh A.; Ahmadi Y.; Knoll P.; Floth A.; Righi S.; Zandieh S.; Meleddu C.; Shariat S.F.; Klingler H.C.; Mirzaei S.; 64Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother Radiopharm 2016,31,277-286","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11307-016-0945-x","volume":"18","author":"Prasad V.","year":"2016","unstructured":"Prasad V.; Steffen I.G.; Diederichs G.; Makowski M.R.; Wust P.; Brenner W.; Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol 2016,18,428-436","journal-title":"Mol Imaging Biol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"Demirci E.","year":"2016","unstructured":"Demirci E.; Sahin O.E.; Ocak M.; Akovali B.; Nematyazar J.; Kabasakal L.; Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun 2016,37,1169-1179","journal-title":"Nucl Med Commun"},{"key":"ref=36","first-page":"10(3), pii: E68","volume":"31","author":"Thomas L.","year":"2017","unstructured":"Thomas L.; Balmus C.; Ahmadzadehfar H.; Essler M.; Strunk H.; Bundschuh R.A.; Assessment of bone metastases in patients with prostate cancer-a comparison between 99mTc-Bonescintigraphy and 68Ga-PSMA PET\/CT. Pharmaceuticals(Basel) 2017,31,10(3), pii: E68","journal-title":"Pharmaceuticals(Basel)"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/RLU.0000000000001296","volume":"41","author":"Blazak J.K.","year":"2016","unstructured":"Blazak J.K.; Thomas P.; Paget disease: a potential pitfall in psma pet for prostate cancer. Clin Nucl Med 2016,41,699-700","journal-title":"Clin Nucl Med"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MNM.0b013e328330adc5","volume":"31","author":"Schillaci O.","year":"2010","unstructured":"Schillaci O.; Calabria F.; Tavolozza M.; Cicci\u00f2 C.; Carlani M.; Caracciolo C.R.; Danieli R.; Orlacchio A.; Simonetti G.; 18F-choline PET\/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010,31,39-45","journal-title":"Nucl Med Commun"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.20063","volume":"39","author":"Hisatomi Y.","year":"2004","unstructured":"Hisatomi Y.; Okumura K.; Nakamura K.; Matsumoto S.; Satoh A.; Nagano K.; Yamamoto T.; Endo F.; Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. Hepatology 2004,39,667-675","journal-title":"Hepatology"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"74159","DOI":"10.18632\/oncotarget.18276","volume":"8","author":"Han X.D.","year":"2017","unstructured":"Han X.D.; Liu C.; Liu F.; Xie Q.H.; Liu T.L.; Guo X.Y.; Xu X.X.; Yang X.; Zhu H.; Yang Z.; 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget 2017,8,74159-74169","journal-title":"Oncotarget"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/pros.21176","volume":"15","author":"Alt K.","year":"2010","unstructured":"Alt K.; Wiehr S.; Ehrlichmann W.; Reischl G.; Wolf P.; Pichler B.J.; Els\u00e4sser-Beile U.; B\u00fchler P.; High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010,15,1413-1421","journal-title":"Prostate"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1039\/C7MT00227K","volume":"15","author":"Andreozzi E.M.","year":"2017","unstructured":"Andreozzi E.M.; Torres J.B.; Sunassee K.; Dunn J.; Walker-Samuel S.; Szanda I.; Blower P.J.; Studies of copper trafficking in a mouse model of Alzheimer\u2019s disease by positron emission tomography: comparison of 64Cu acetate and 64CuGTSM. Metallomics 2017,15,1622-1633","journal-title":"Metallomics"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/00039896.1986.9936705","volume":"41","author":"Ishihara N.","year":"1986","unstructured":"Ishihara N.; Matsushiro T.; Biliary and urinary excretion of metals in humans. Arch Environ Health 1986,41,324-330","journal-title":"Arch Environ Health"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cpet.2016.12.004","volume":"12","author":"Hofman M.S.","year":"2017","unstructured":"Hofman M.S.; Iravani A.; Gallium-68 prostate-specific membrane antigen PET imaging. PET Clin 2017,12,219-234","journal-title":"PET Clin"},{"key":"ref=45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145755","volume":"10","author":"Gourni E.","year":"2015","unstructured":"Gourni E.; Canovas C.; Goncalves V.; Denat F.; Meyer P.T.; Maecke H.R.; (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of psma-positive tumors. PLoS One 2015,10","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MNM.0000000000000372","volume":"36","author":"Haroon A.","year":"2015","unstructured":"Haroon A.; Zanoni L.; Celli M.; Zakavi R.; Beheshti M.; Langsteger W.; Fanti S.; Emberton M.; Bomanji J.; Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl Med Commun 2015,36,1065-1075","journal-title":"Nucl Med Commun"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00259-011-2030-7","volume":"39","author":"Schillaci O.","year":"2012","unstructured":"Schillaci O.; Calabria F.; Tavolozza M.; Caracciolo C.R.; Finazzi-Agr\u00f2 E.; Miano R.; Orlacchio A.; Danieli R.; Simonetti G.; Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET\/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012,39,589-596","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.2967\/jnumed.115.169599","volume":"57","author":"Spick C.","year":"2016","unstructured":"Spick C.; Herrmann K.; Czernin J.; Evaluation of Prostate Cancer with 11C-Acetate PET\/CT. J Nucl Med 2016,57,30S-37S","journal-title":"J Nucl Med"},{"key":"ref=49","first-page":"56","volume":"8","author":"Schuster D.M.","year":"2007","unstructured":"Schuster D.M.; Votaw J.R.; Nieh P.T.; Yu W.; Nye J.A.; Master V.; Bowman F.D.; Issa M.M.; Goodman M.M.; Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET\/CT in prostate carcinoma. J Nucl Med 2007,8,56-63","journal-title":"J Nucl Med"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/RLU.0000000000001789","volume":"42","author":"Teoh E.J.","year":"2017","unstructured":"Teoh E.J.; Tsakok M.T.; Bradley K.M.; Hyde K.; Subesinghe M.; Gleeson F.V.; Recurrent malignant melanoma detected on 18F-fluciclovine PET\/CT imaging for prostate cancer. Clin Nucl Med 2017,42,803-804","journal-title":"Clin Nucl Med"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/RLU.0000000000001381","volume":"41","author":"Vardhanabhuti V.","year":"2016","unstructured":"Vardhanabhuti V.; Lo A.W.; Lee E.Y.; Law S.Y.; Dual-tacer PET\/CT using 18F-FDG and 11C-Acetate in gastric adenocarcinoma with liver metastasis. Clin Nucl Med 2016,41,864-865","journal-title":"Clin Nucl Med"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-010-1678-8","volume":"38","author":"Calabria F.","year":"2011","unstructured":"Calabria F.; D\u2019Auria S.; Sannino P.; Schillaci O.; A case of thymoma detected by 18F-choline positron emission tomography\/computed tomography. Eur J Nucl Med Mol Imaging 2011,38,602","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/RLU.0000000000001959","volume":"43","author":"Anconina R.","year":"2018","unstructured":"Anconina R.; Hod. N.; Levin, D.; Ezroh Kazap, D., Lantsberg, S. incidental detection of metastatic malignant melanoma on 68Ga-prostate-specific membrane antigen PET\/CT imaging: Correlative imaging with FDG PET\/CT and review of the literature. Clin Nucl Med 2018,43,204-206","journal-title":"Clin Nucl Med"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/RLU.0000000000001948","volume":"43","author":"Oh G.","year":"2018","unstructured":"Oh G.; Miles K.; Subacute cerebellar infarction with uptake on 68Ga-Prostate-specific membrane antigen PET\/CT. Clin Nucl Med 2018,43,134-135","journal-title":"Clin Nucl Med"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/RLU.0000000000001935","volume":"43","author":"Jochumsen M.R.","year":"2018","unstructured":"Jochumsen M.R.; Gormsen L.C.; Nielsen G.L.; 68Ga-PSMA avid primary adenocarcinoma of the lung with complementary low 18F-FDG uptake. Clin Nucl Med 2018,43,117-119","journal-title":"Clin Nucl Med"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/RLU.0000000000001927","volume":"43","author":"Jochumsen M.R.","year":"2018","unstructured":"Jochumsen M.R.; Bouchelouche K.; Intense 68Ga-PSMA Uptake in Diverticulum of the Sigmoid Colon. Clin Nucl Med 2018,43,110-111","journal-title":"Clin Nucl Med"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/MNM.0000000000000571","volume":"37","author":"Bilgin R.","year":"2016","unstructured":"Bilgin R.; Erg\u00fcl N.; \u00c7ermik T.F.; Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand. Nucl Med Commun 2016,37,1197-1205","journal-title":"Nucl Med Commun"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40336-017-0249-4","volume":"5","author":"Calabria F.","year":"2017","unstructured":"Calabria F.; Fifty shades of meningioma: Challenges and perspectives of different PET molecular probes. Clin Transl Imaging 2017,5,403-405","journal-title":"Clin Transl Imaging"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2016.11.002","volume":"46","author":"Green M.A.","year":"2017","unstructured":"Green M.A.; Eitel J.A.; Fletcher J.W.; Mathias C.J.; Tann M.A.; Gardner T.; Koch M.O.; Territo W.; Polson H.; Hutchins G.D.; Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer. Nucl Med Biol 2017,46,32-35","journal-title":"Nucl Med Biol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/RLU.0000000000000303","volume":"39","author":"Calabria F.","year":"2014","unstructured":"Calabria F.; Chiaravalloti A.; Schillaci O.; (18)F-choline PET\/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer. Clin Nucl Med 2014,39,122-130","journal-title":"Clin Nucl Med"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T20:18:08Z","timestamp":1607890688000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172126\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,10,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471012666190515090755","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}